Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07100288

Anatomopathological Analysis of the Infundibulopelvic Ligament in Patients With Ovarian Cancer

Involvement of the infundibulopelvic ligament in ovarian cancer may be associated with decreased survival and related to paraaortic lymph node metastasis

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Ovarian Cancer Adnexal Diseases Endocrine Gland Neoplasms Endocrine System Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Female Genital Neoplasms, Female Gonadal Disorders Neoplasms Neoplasms by Site Ovarian Adenocarcinoma Ovarian Cancer (OvCa) Ovarian Diseases Ovarian Neoplasms Urogenital Diseases Urogenital Neoplasms

Age range

18 year and older

Sex eligibility

Female

Study type

Observational

Primary location

Complejo Universitario Insular Materno Infantil de Las Palmas

Las Palmas de Gran Canaria, Spain

Location status: Recruiting

Location contact

Alicia Martin Martinez, phd

CONTACT

[email protected]

+34649088104

Alicia Martín Martínez, MD

SUB_INVESTIGATOR

Andres Rave, MD

SUB_INVESTIGATOR

DANIEL GONZALEZ, MD

SUB_INVESTIGATOR

Jesus Guijarro, MD

SUB_INVESTIGATOR

Octavio Arencibia Sanchez, MD

SUB_INVESTIGATOR

CONTACT

[email protected]

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • ◦ Patients with epithelial ovarian cancer, including high- and low-grade serous, high- and low-grade endometrioid, mucinous (expansile and infiltrative types), and carcinosarcoma.
  • FIGO 2014 stage IA-IVB.
  • Patients undergoing primary surgery or interval surgery after 3-4 or 6 cycles of chemtherapy
  • Patients with no residual disease after surgery.
  • Patients with ECOG performance status 0-1.

Exclusion criteria

  • ◦ Patients without epithelial ovarian cancer.
  • Patients with ECOG 2-4.
  • Patients who do not consent to participate in the study.
  • Patients who did not undergo complete staging surgery (including hysterectomy, bilateral salpingo-oophorectomy, pelvic and para-aortic lymphadenectomy, and omentectomy) or with residual disease after cytoreductive surgery.

Treatment and study plan

resection of infundibulopelvic ligament

Other

Therefore, this study also aims to perform bilateral infundibulopelvic ligament resection (at least 8 cm in length) during surgery for ovarian cancer patients

Primary outcomes

  1. metastasis in infundibulopelvic ligament

    Time frame: Through study completion, an average of 5 year

    To analyze the percentage of infundibulopelvic ligament involvement by cancer in patients with FIGO stage IA-IVB ovarian cancer.

Secondary outcomes

  1. Presence of paraaortic lymph node metastasis

    Time frame: Through study completion, an average of 5 year

    Evaluation of histologically positive para-aortic lymph nodes in patients with metastasis in the infundibulopelvic ligament

Other outcomes

  1. Disease Free Survival

    Time frame: 3 months, 6 months, 9 months, 12 months, 15 months, 18 months, 21 months, 24 months, 27 months, 30 months, 33 months, 36 months, 42 months, 48 months, 54 months, 60 months

    Impact of infundibulopelvic ligament involvement on Disease specific survival

  2. Assessment of complications

    Time frame: during surgery, at hospital discharge, day 30

    Assessment of perioperative complications and site effects of infundibulopelvic ligament resection

  3. Overall survival (OS)

    Time frame: 60 months

    Impact of infundibulopelvic ligament involvement on overall survival

Study contacts

Contact information is provided by the study sponsor or research team.

beatriz NAVARRO SANTANA, pHD

CONTACT

[email protected]

+34620151146

Sponsors and collaborators

Lead sponsor

Complejo Hospitalario Universitario Insular Materno Infantil

Other

Registry information

Acronym: INFPELV

Important dates

Study start
2025
Primary completion
2030
Study completion
2030
First posted
Aug 3, 2025
Registry last updated
Aug 3, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.